drugset
drugset / Trial / NCT04440943

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

NCT04440943 ↗

Phase 1 Completed 27 enrolled Celldex Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.

Timeline

Start
2020-08-04
Primary completion
2023-04-06
Completion
2023-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CDX-527 Unknown — Other

Indications

breast cancer cholangiocarcinoma colorectal cancer esophageal cancer fallopian tube cancer gastric cancer head and neck cancer non-small cell lung carcinoma ovarian cancer primary peritoneal carcinoma renal cell carcinoma urothelial carcinoma